← All trials
NCT04173169
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 814
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yale UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Institutes of Health (NIH)Study director
- Yale UniversityStudy director
- Yale UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillCollaborator
- University of North Carolina at Chapel HillStudy director
- University of Colorado, DenverCollaborator
- University of Colorado, DenverStudy director
- Northwestern UniversityCollaborator
- Northwestern UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.